Nigeria set to open vaccine production eyes to make $280mn

Nigeria is set to embark on an ambitious journey to produce vaccines for local consumption and export, with hopes to generate $280 million annually. The government's plan aims to cater for the vaccination needs of up to 7 million children in the country. This initiative marks the country's second attempt at vaccine manufacturing, with the last production phase halting in 1991 due to a lack of enabling policies and government support. Dr. Francis Ojaidu, a senior advisor and national pneumonia coordinator, shared insights on the reemergence of the vaccine production sector in Nigeria. The government's vision includes establishing a sustainable framework for vaccine production, including the involvement of private sector partnerships and development finance. By 2020, Nigeria anticipates generating $280 million from vaccine exports if the initiative gains traction. The shift towards local vaccine production comes as Nigeria transitions away from dependency on international organizations like Gavi for vaccine supply. The move signifies a strategic effort to meet the demands of a rapidly growing population and reduce the country's reliance on imported vaccines, which have often led to resistance from foreign vaccine suppliers. Dr. Ojaidu emphasized the importance of government commitment and the creation of an enabling environment to support the growth of the local vaccine industry. He advocated for a public-private partnership approach to ensure sustainability and meet the demand-supply equilibrium in the market. In terms of standardization and approval for vaccine exports, Dr. Ojaidu assured that Nigeria has the capacity to meet global standards based on its successful history of producing quality healthcare products like chlorhexidine and oxygen tubes. As the country looks towards exporting vaccines, adherence to international best practices and standards will be crucial to gaining trust and acceptance in the global market. The potential for Nigeria to become a key player in vaccine production not only serves as a significant economic opportunity but also positions the country as a self-reliant player in the healthcare industry.